Clinical trial · Observational
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene
NCT00444795CI-TRIAL-00025737completedResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To monitor use in real practice including adverse events and efficacy on Sutent capsules (Sunitinib malate)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastrointestinal Stromal Tumors | Gastrointestinal Stromal Tumor | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sunitinib malate | Drug | Sunitinib | ALIAS |
Design
Arms and outcomes
Arms (3)
- label
- 1
- description
- patients diagnosed as GIST after disease progression on or intolerance to imatinib mesylate
- interventionNames
- Drug: Sunitinib malate
- label
- 2
- description
- patients diagnosed as advanced RCC
- interventionNames
- Drug: Sunitinib malate
- label
- 3
- description
- patients diagnosed as unresectable, well-differentiated advanced and/or metastatic pancreatic neuroendocrine carcinoma
- interventionNames
- Drug: sunitinib malate
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients diagnosed as gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate, or advanced renal cell carcinoma (aRCC) will be included in the study, or patients diagnosed as unresectable, well-differentiated advanced and/or metastatic pancreatic neuroendocrine carcinoma. Exclusion Criteria: * Any patient who does not agree that Pfizer and companies working with Pfizer use his/her information will be excluded. * Patients with hypersensitivity to sunitinib malate or to any other component of Sutent
References
Publications (0)
Data not yet available
No reference posted for this study.